Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Shares of Indiana-based Endocyte have shot up more than 50 percent in pre-market trading after Swiss pharma giant Novartis announced it was acquiring the company for $2.1 billion in cash. The deal will allow the company to expand its radiopharmaceuticals business.
Discovery Life Sciences, a leading research biobank located in Los Osos, California, recently got much, much bigger via a four-company merger. Ann Dover, Discovery’s founder, president and CEO, took time to speak with BioSpace about the merger and the new identity of the company.
China’s Innovent Biologics reportedly is continuing with its plans to raise $423 million in its Hong Kong IPO. If so, it would be the biggest biotech IPO out of Hong Kong this year.
The U.S. Department of Justice has given preliminary approval for CVS’ $69 billion acquisition of Aetna after Aetna divested its Medicare Part D business.
Allogene Therapeutics began trading on the Nasdaq Stock Exchange today under the ALLO ticker. The price was at the top of its range, $18 per share. The company plans to raise $288 million with the sale of about 16 million shares.
Clinigen Group plc announces that it has today completed the acquisition of iQone Healthcare Holding (‘iQone’), which was announced on 27 September 2018 (the “Acquisition”).
MeiraGTx, headquartered in London, UK, acquired Vector Neurosciences in an all-stock deal. As part of the deal, MeiraGTx picks up Vector’s Phase II gene therapy program for Parkinson’s disease.
Orchard Therapeutics, with locations in Boston and London, UK, received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for OTL-300, a lentiviral gene therapy for transfusion-dependent beta-thalassemia (TDBT).
Despite an ongoing lawsuit over alleged theft of intellectual property, San Francisco-based Twist Bioscience plans to go public with an $86 million initial public offering.
Guardant Health went on the Nasdaq yesterday under the symbol GH. Shares climbed almost 70 percent on the first day of trading, selling 12.5 million shares at $19 per share in the initial public offering (IPO).